FDA Adds Warning Label to RSV Vaccines Abrysvo and Arexvy
By Lori Solomon HealthDay Reporter
MONDAY, Jan. 13, 2025 -- The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information for the Abrysvo (Pfizer) and Arexvy (GlaxoSmithKline) respiratory syncytial virus (RSV) vaccines to include warnings and precautions about the risk for Guillain-Barré syndrome (GBS).
For each vaccine, postmarketing observational studies suggest an increased risk of GBS during the 42 days following vaccination.
Arexvy has been approved for the prevention of lower respiratory tract disease caused by RSV in all individuals 60 years of age and older and for those aged 50 to 59 years at increased risk. Abrysvo has been approved for the prevention of lower respiratory tract disease caused by RSV in all individuals 60 years of age and older, as well as individuals aged 18 to 59 years at increased risk. Abrysvo is also approved for pregnant individuals at 32 through 36 weeks of gestational age for the prevention of lower respiratory tract disease caused by RSV in infants from birth through 6 months of age.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Many Not Up to Date With Vaccines Would Accept Shots During ED Visits
MONDAY, Aug. 11, 2025 -- Many individuals who are not up to date with recommended vaccinations would accept vaccines if offered during an emergency department visit, according to...
Study Estimates COVID-19 Vaccinations Prevented More Than 2.5 Million Deaths in 2020 to 2024
MONDAY, Aug. 4, 2025 -- COVID-19 vaccination during 2020 to 2024 was beneficial, but estimates are more conservative than previous calculations that focused on the first year of...
COVID-19 Vaccine Boosters Aid Outcomes in Patients With Cancer
TUESDAY, July 29, 2025 -- COVID-19 vaccination boosters protect people with cancer developing from severe COVID-19, according to a study published online July 17 in JAMA...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.